CiMaas, a biotech company based in Maastricht, develops Natural Killer (NK) cell therapies for cancer treatment. Founded as a spin-off from Maastricht University, the company focuses on safe, effective immunotherapies for metastatic and late-stage cancers.
We invested in CiMaas through 819 Evergreen Fund I.
Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...
Continue readingDeventer, 10 February 2026 – 819 Capital Partners announces the acquisition of Chalet.nl, a well-established Dutch touroperator that has been a leading authority in winter sports holidays for more than 25 years. Chalet.nl specializes in the organization and rental of chalets and apartments in leading winter sports destinations across France, Austria, Switzerland and Italy. The company has built a strong online presence and is known for its reliable service, personal approach, and deep expertise in...
Continue reading